ProNAi Therapeutics (DNAI) Shares are Down -4.71%

ProNAi Therapeutics (DNAI) has risen sharply, recording gains of 0.55% in the past 4 weeks. However, the stock has corrected -4.71% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.1% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 2.1% and the 50-Day Moving Average is 4.49%.The 200 Day SMA reached 66.55%


ProNAi Therapeutics (NASDAQ:DNAI): The stock opened in the green at $1.9 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $1.9 and a low of $1.81 for the day. The stock did not find buyers even at the lows and closed at $1.82 recording a loss of -3.70%. 726,943 shares exchanged hands during the trading day. The stock had closed at $1.82 in the previous days trading.

ProNAi Therapeutics (DNAI) : Average target price received by ProNAi Therapeutics (DNAI) is $2.5 with an expected standard deviation of $0.71. The most aggressive target on the stock is $3, whereas the most downbeat target is $2. 2 financial analysts are currently covering the stock.

ProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company develops and commercializes a portfolio of therapeutics based on its deoxyribonucleic acid interference (DNAi) technology platform for patients with cancer and hematological diseases. The Companys lead DNAi product candidate, PNT2258, treat cancers that overexpress BCL2, an oncogene known to be dysregulated in many types of cancer. Its platform consists of two components: Rationally-Designed DNAi Oligonucleotides and Lipid Nanoparticle (LNP) Delivery Technology. The Company has conducted two clinical trials for PNT2258: a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkins lymphoma (NHL). It has initiated Wolverine, a Phase II trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.